Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation

MT Newswires Live

2025/02/07

Eton Pharmaceuticals (ETON) said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.

The company said the patent expires in 2044 and is expected to be listed in the FDA's Orange Book once ET-600 is approved.

Eton said it has another patent application related to the ET-600 product that is currently under review.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2509571735"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509571735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509571735?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-07 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509571735","market":"hk","top_or_hot":-1,"title":"Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation","media":"MT Newswires Live","content":"<html><body><p> Eton Pharmaceuticals (ETON) said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.</p><p>The company said the patent expires in 2044 and is expected to be listed in the FDA's <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book once ET-600 is approved.</p><p>Eton said it has another patent application related to the ET-600 product that is currently under review.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEton Pharmaceuticals Says US Patent Granted for ET-600 Formulation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-07 20:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Eton Pharmaceuticals (ETON) said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.</p><p>The company said the patent expires in 2044 and is expected to be listed in the FDA's <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book once ET-600 is approved.</p><p>Eton said it has another patent application related to the ET-600 product that is currently under review.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ET","symbol_name":"Energy Transfer LP","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509571735","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509571735","pubTimestamp":1738930075,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eton Pharmaceuticals  said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.The company said the patent expires in 2044 and is expected to be listed in the FDA's Orange Book once ET-600 is approved.Eton said it has another patent application related to the ET-600 product that is currently under review.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ET":"Energy Transfer LP","BK4007":"制药","BK4588":"碎股","BK4590":"PTP","BK4561":"索罗斯持仓","BK4585":"ETF&股票定投概念","ETON":"Eton Pharmaceuticals, Inc.","BK4581":"高盛持仓","BK4144":"石油与天然气的储存和运输"},"translate_title":"Eton Pharmaceuticals表示ET-600配方获得美国专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ET":1,"ETON":0.9},"content_text":"Eton Pharmaceuticals (ETON) said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.The company said the patent expires in 2044 and is expected to be listed in the FDA's Orange Book once ET-600 is approved.Eton said it has another patent application related to the ET-600 product that is currently under review.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}